Follow the Chordia Therapeutics株式会社 share price and the full directors' dealings record of the company, a listed equity based in Japan. Shares trade on the JP market, under the authority of EDINET (Japan FSA). Market capitalisation: €122.7bn. The latest transaction was filed on 22 May 2026 (Holding update). Among the most active insiders: SBI Investment Co., Ltd.. Every trade is openly available.
29
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
24Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 10,321 of 28,548 companies
58.4
score / 100
Value
55
Quality
62
FCF yld4.6%
Earn yld5.4%
EV/EBITDA16.4x
ROE4.6%
Gross mgn45%
Net mgn30%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Chordia Therapeutics is a company listed on the XTKS market, specializing in the development of innovative therapies. It focuses on research and commercialization of treatments for various diseases.